Max Hallin
Impact in
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research
-
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Angiogenesis and VEGF in Cancer 2
- PI3K/AKT/mTOR signaling in cancer 2
- Protein Degradation and Inhibitors 1
- Histone Deacetylase Inhibitors Research 1
- Oncology 4
- Peptidase Inhibition and Analysis 1
- Co-authors
- Michele McTigue (2 shared papers)Maren L. Grazzini (2 shared papers)Brion W. Murray (2 shared papers)Karin Amundson (2 shared papers)Dana D. Hu‐Lowe (2 shared papers)Shinji Yamazaki (2 shared papers)Steve Bender (1 shared paper)David A. Rewolinski (1 shared paper)
- Journals
- Clinical Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)Journal of Hematology & Oncology (1 paper)Cancer Research (1 paper)
- Partner nations
- United States
In The Last Decade
Max Hallin
6 papers receiving 620 citations
Max Hallin's Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 276
- Cancer Research 142
- Pulmonary and Respiratory Medicine 260
- Molecular Biology 362
- Genetics 34
Countries citing papers authored by Max Hallin
This map shows the geographic impact of Max Hallin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hallin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hallin more than expected).
Fields of papers citing papers by Max Hallin
This network shows the impact of papers produced by Max Hallin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hallin. The network helps show where Max Hallin may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Hallin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Hit paper breakdown → | 2008 | 515 |
| 2 | 2017 | 49 | |
| 3 | 2009 | 45 | |
| 4 | 2021 | 9 | |
| 5 | PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2 | 2007 | 7 |
| 6 | 2020 | 7 |
About Max Hallin
Max Hallin is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 6 papers that have together received 632 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Renal cell carcinoma treatment (2 papers), Peptidase Inhibition and Analysis (1 paper), Microtubule and mitosis dynamics (1 paper), Protein Degradation and Inhibitors (1 paper), Cancer, Hypoxia, and Metabolism (1 paper) and Histone Deacetylase Inhibitors Research (1 paper). The work is most often cited by research in Oncology (276 citations), Cancer Research (142 citations), Pulmonary and Respiratory Medicine (260 citations), Molecular Biology (362 citations) and Genetics (34 citations). Max Hallin has collaborated with scholars based in United States. Frequent co-authors include Michele McTigue, Maren L. Grazzini, Brion W. Murray, Karin Amundson, Dana D. Hu‐Lowe, Shinji Yamazaki, Steve Bender, David A. Rewolinski, Helen Y. Zou and Patrick M. O’Connor. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Journal of Hematology & Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.